250 related articles for article (PubMed ID: 19029516)
1. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Sorenson EJ; Windbank AJ; Mandrekar JN; Bamlet WR; Appel SH; Armon C; Barkhaus PE; Bosch P; Boylan K; David WS; Feldman E; Glass J; Gutmann L; Katz J; King W; Luciano CA; McCluskey LF; Nash S; Newman DS; Pascuzzi RM; Pioro E; Sams LJ; Scelsa S; Simpson EP; Subramony SH; Tiryaki E; Thornton CA
Neurology; 2008 Nov; 71(22):1770-5. PubMed ID: 19029516
[TBL] [Abstract][Full Text] [Related]
2. A placebo-controlled trial of insulin-like growth factor-I in amyotrophic lateral sclerosis. European ALS/IGF-I Study Group.
Borasio GD; Robberecht W; Leigh PN; Emile J; Guiloff RJ; Jerusalem F; Silani V; Vos PE; Wokke JH; Dobbins T
Neurology; 1998 Aug; 51(2):583-6. PubMed ID: 9710040
[TBL] [Abstract][Full Text] [Related]
3. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2002; (3):CD002064. PubMed ID: 12137643
[TBL] [Abstract][Full Text] [Related]
4. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND).
Miller RG; Mitchell JD; Lyon M; Moore DH
Amyotroph Lateral Scler Other Motor Neuron Disord; 2003 Sep; 4(3):191-206. PubMed ID: 13129806
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease.
Beauverd M; Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2012 Nov; 11():CD002064. PubMed ID: 23152212
[TBL] [Abstract][Full Text] [Related]
6. A phase II-III trial of olesoxime in subjects with amyotrophic lateral sclerosis.
Lenglet T; Lacomblez L; Abitbol JL; Ludolph A; Mora JS; Robberecht W; Shaw PJ; Pruss RM; Cuvier V; Meininger V;
Eur J Neurol; 2014 Mar; 21(3):529-36. PubMed ID: 24447620
[TBL] [Abstract][Full Text] [Related]
7. A double-blind placebo-controlled clinical trial of subcutaneous recombinant human ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. ALS CNTF Treatment Study Group.
Neurology; 1996 May; 46(5):1244-9. PubMed ID: 8628460
[TBL] [Abstract][Full Text] [Related]
8. Effect of recombinant human insulin-like growth factor-I on progression of ALS. A placebo-controlled study. The North America ALS/IGF-I Study Group.
Lai EC; Felice KJ; Festoff BW; Gawel MJ; Gelinas DF; Kratz R; Murphy MF; Natter HM; Norris FH; Rudnicki SA
Neurology; 1997 Dec; 49(6):1621-30. PubMed ID: 9409357
[TBL] [Abstract][Full Text] [Related]
9. A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis.
Cudkowicz ME; Shefner JM; Schoenfeld DA; Brown RH; Johnson H; Qureshi M; Jacobs M; Rothstein JD; Appel SH; Pascuzzi RM; Heiman-Patterson TD; Donofrio PD; David WS; Russell JA; Tandan R; Pioro EP; Felice KJ; Rosenfeld J; Mandler RN; Sachs GM; Bradley WG; Raynor EM; Baquis GD; Belsh JM; Novella S; Goldstein J; Hulihan J;
Neurology; 2003 Aug; 61(4):456-64. PubMed ID: 12939417
[TBL] [Abstract][Full Text] [Related]
10. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: clinical, neuroimaging, and hormonal results.
Saccà F; Quarantelli M; Rinaldi C; Tucci T; Piro R; Perrotta G; Carotenuto B; Marsili A; Palma V; De Michele G; Brunetti A; Brescia Morra V; Filla A; Salvatore M
J Neurol; 2012 Jan; 259(1):132-8. PubMed ID: 21706151
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human insulin-like growth factor I (rhIGF-I) for amyotrophic lateral sclerosis/motor neuron disease.
Mitchell JD; Wokke JH; Borasio GD
Cochrane Database Syst Rev; 2007 Oct; (4):CD002064. PubMed ID: 17943766
[TBL] [Abstract][Full Text] [Related]
12. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II.
Lacomblez L; Bensimon G; Leigh PN; Guillet P; Meininger V
Lancet; 1996 May; 347(9013):1425-31. PubMed ID: 8676624
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial.
Howe CL; Bergstrom RA; Horazdovsky BF
Neurology; 2009 Oct; 73(15):1247; author reply 1247-8. PubMed ID: 19822878
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
15. Trial of Sodium Phenylbutyrate-Taurursodiol for Amyotrophic Lateral Sclerosis.
Paganoni S; Macklin EA; Hendrix S; Berry JD; Elliott MA; Maiser S; Karam C; Caress JB; Owegi MA; Quick A; Wymer J; Goutman SA; Heitzman D; Heiman-Patterson T; Jackson CE; Quinn C; Rothstein JD; Kasarskis EJ; Katz J; Jenkins L; Ladha S; Miller TM; Scelsa SN; Vu TH; Fournier CN; Glass JD; Johnson KM; Swenson A; Goyal NA; Pattee GL; Andres PL; Babu S; Chase M; Dagostino D; Dickson SP; Ellison N; Hall M; Hendrix K; Kittle G; McGovern M; Ostrow J; Pothier L; Randall R; Shefner JM; Sherman AV; Tustison E; Vigneswaran P; Walker J; Yu H; Chan J; Wittes J; Cohen J; Klee J; Leslie K; Tanzi RE; Gilbert W; Yeramian PD; Schoenfeld D; Cudkowicz ME
N Engl J Med; 2020 Sep; 383(10):919-930. PubMed ID: 32877582
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study.
de la Rubia JE; Drehmer E; Platero JL; Benlloch M; Caplliure-Llopis J; Villaron-Casales C; de Bernardo N; AlarcÓn J; Fuente C; Carrera S; Sancho D; GarcÍa-Pardo P; Pascual R; JuÁrez M; Cuerda-Ballester M; Forner A; Sancho-Castillo S; Barrios C; Obrador E; Marchio P; Salvador R; Holmes HE; Dellinger RW; Guarente L; Estrela JM
Amyotroph Lateral Scler Frontotemporal Degener; 2019 Feb; 20(1-2):115-122. PubMed ID: 30668199
[TBL] [Abstract][Full Text] [Related]
17. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.
Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S
Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial.
Ludolph AC; Schuster J; Dorst J; Dupuis L; Dreyhaupt J; Weishaupt JH; Kassubek J; Weiland U; Petri S; Meyer T; Grosskreutz J; Schrank B; Boentert M; Emmer A; Hermann A; Zeller D; Prudlo J; Winkler AS; Grehl T; Heneka MT; Wollebæk Johannesen S; Göricke B;
Lancet Neurol; 2018 Aug; 17(8):681-688. PubMed ID: 29934198
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial.
Gordon PH; Moore DH; Miller RG; Florence JM; Verheijde JL; Doorish C; Hilton JF; Spitalny GM; MacArthur RB; Mitsumoto H; Neville HE; Boylan K; Mozaffar T; Belsh JM; Ravits J; Bedlack RS; Graves MC; McCluskey LF; Barohn RJ; Tandan R;
Lancet Neurol; 2007 Dec; 6(12):1045-53. PubMed ID: 17980667
[TBL] [Abstract][Full Text] [Related]
20. Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.
Andrews JA; Meng L; Kulke SF; Rudnicki SA; Wolff AA; Bozik ME; Malik FI; Shefner JM
JAMA Neurol; 2018 Jan; 75(1):58-64. PubMed ID: 29181534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
